RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
International event brings world's top cancer doctors to Queen's

Sep 1, 2009 - 4:00:00 AM
Professor Peter Gregson, Vice-Chancellor of Queen's University, said: Cancer is a disease feared around the world. Its impact is global. It therefore demands a global response, a response where leading researchers work together across academic disciplines and geographical frontiers.

 
[RxPG] Over 200 of the world's top cancer specialists will be in Belfast this week to share their knowledge at an International Cancer Symposium organised by Queen's University.

The event, being hosted by the Centre for Cell Biology and Cancer Research (CCRCB) on Wednesday and Thursday, will be attended by leading academics from across America, Australia and Europe, including those from Harvard Medical School in Boston and from Oxford and Cambridge universities.

One in three people in Northern Ireland will be diagnosed with cancer at some stage in their life and the conference aims to build on international links to improve cancer treatments for sufferers.

CCRCB is currently carrying out around 50 national and international clinical trials into various cancers with the aim of offering patients new treatment options which will have the best outcomes for them as well as fewer and less severe side effects.

The Centre has three successful spin-out companies - ALMAC Diagnostics, Fusion Antibodies and I-Path - employing nearly 200 people.

Two young researchers will present their studies at the event entitled 'Cancer: Found in Translation'.

Dr Kelly Redmond from Newry and Dr Jenny Quinn from Londonderry will be among the international line-up of speakers sharing their knowledge about the latest developments in cancer research.

Dr Redmond will speak about her research into a molecule called FLIP which blocks chemotherapy from working in non-small cell lung cancer (NSCLC), the leading cause of cancer death in the US and Europe. By decreasing FLIP levels in NSCLC cells they become more sensitive to chemotherapy.

She said: This is an important finding as it suggests that if we can decrease FLIP levels with new types of drugs, the cancer but not the normal lung tissues will be more effectively killed by chemotherapy.

Dr Quinn's research has focused on trying to find the best chemotherapy treatment for both breast and ovarian cancer sufferers.

She has investigated the effects of the drugs on patients with and without the BRCA1 gene, which controls cell growth in normal breast and ovarian cells, preventing tumours forming.

Ovarian cancer patients are generally treated with both platinum and taxane based chemotherapy. However Dr Quinn has found that patients without BRCA1 benefited significantly from platinum only chemotherapy while those with normal BRCA1 levels gained an almost two year improvement in survival if they also received taxane chemotherapy.

Dr Quinn said: We are now planning further studies that may ultimately lead to the development of a test involving BRCA1 for determining the best chemotherapy treatments for patients with ovarian cancer. Such a test may also prove useful in breast, lung and prostate cancer.

The symposium has been organised by Professor Dennis McCance, Director of the Centre for Cancer Research and Cell Biology at Queen's University, who leads a team of around 250 staff.

He said: This event reflects CCRCB's achievements in cancer research and highlights our aspirations to see our knowledge about basic research translated into better and more effective treatments for patients.

Through clinical trials we are working to offer patients new treatment options which will have the best outcomes for them.

We are using novel ways to select treatments and personalise or tailor them to the patient's particular mutations.

The calibre of speakers coming to our conference and the international links that we have formed demonstrate that our work is considered of a world-class standard.

Professor Peter Gregson, Vice-Chancellor of Queen's University, said: Cancer is a disease feared around the world. Its impact is global. It therefore demands a global response, a response where leading researchers work together across academic disciplines and geographical frontiers.

We are pleased to bring together leading academics and researchers from across the world to discuss innovative scientific and medical research that will help those who suffer from cancer.




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)